Barrier Therapeutics Inactive 10-K2007 FY Annual report

Filed: 12 Mar 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Good

New words: accompanyingManagement, Amgen, antimicrobial, arrive, asmalassezia, awaiting, back, backed, batch, BioScience, Biotech, Braham, campaign, career, CIRD, colonizing, Coria, counter, cycle, cyclosporine, DFB, discolored, Duo, eighteen, Enbrel, entry, EU, exceeded, Exit, exiting, Extina, Foam, formal, FSP, furfur, Glasgow, Harvard, Healthpoint, hierarchy, highest, housing, hydrochloride, illiquidity, inInternal, inventor, kit, Laureate, learning, led, LIBOR, lowest, lump, Lynch, median, Merrill, mortgage, motivate, Neoral, Nobel, nonfinancial, nonrefundable, notification, oz, partnership, pervasive, petition, Philosophy, Phyton, Pledge, postdoctoral, promising, pyrithione, Question, Quinnova, RB, reconsideration, recurring, regular, remedy, Remicade, residential, revolving, rolling, SAB, Sanico, scientist, Scotland, shampoo, Shroot, simplified, sixty, superficial, talarozole, television, Tersi, thirty, transient, tube, unconsolidated, vapitidine, vitamin, vulvovaginal, waiting, warrant, weekly, Woodward, write, writing, Xolex

Removed: abroad, academic, Africa, aggregating, applying, Archer, Argentina, arising, asP, Atopik, Australia, award, Azoline, Biology, birth, caption, Caribbean, Central, Clarion, cold, confirmatory, congenital, conventional, deficiency, Denmark, designee, dry, endpoint, enrolling, enterprise, fit, forecasted, Fractional, Germany, Greiner, Haddonfield, half, harmed, hedge, Hershey, hyperpigmented, incremental, Indonesia, internally, IPO, issuable, Italy, ketanserin, Latin, Liarozole, Luxembourg, manifestation, measured, Mexico, Milton, nominal, ovale, overcolonizing, oxatomide, penetration, Peru, ratably, raw, redeemed, secondary, South, stopping, strict, suitable, Temple, thereunder, typical, unavailable, unsatisfactory, vaginal, variability, Venezuela, wide, women, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Barrier Therapeutics similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.3

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Barrier Therapeutics, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dennis P Reilly, Vice President, Principal Accounting Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ DENNIS P. REILLY*

Dennis P. Reilly

Vice President, Finance

(Principal Accounting Officer)

March 12, 2008

*	A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.